

**Unlocking Epigenetic Secrets from the Uterus:
Therapeutic Options for Advanced and Recurrent Endometrial Cancer
Tweeterial #2 References**

Tweet 3:

Makker V. Breaking new ground in the treatment of advanced endometrial cancer. *Oncology*. 2019;19:239-242.

The Cancer Genome Atlas Research Network (TCGA). Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013;497:67-73.

Tweet 5:

Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). *J Clin Oncol*. 2020;38:3841-3850.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 3.2021—June 03, 2021. Accessed June 15, 2021. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Tweet 6:

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 3.2021—June 03, 2021. Accessed June 15, 2021. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary and advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. *Int J Gynecol Cancer*. 2008;18:803-808.

Tweet 7:

Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. *Ann Oncol*. 2007;18:409-420.

Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary and advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. *Int J Gynecol Cancer*. 2008;18:803-808.

Tweet 8:

van Weelden WJ, Massuger LFAG, Pijnenborg JMA, Romano A. Anti-estrogen treatment in endometrial cancer: a systematic review. *Front Oncol*. 2019;9:359.

Campos SM, Cohn DE. Treatment of metastatic endometrial cancer. *UpToDate*. Last updated November 11, 2020. <https://www.uptodate.com/> Accessed January 19, 2021.

Tweet 10:

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 3.2021—June 03, 2021. Accessed June 15, 2021. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Tweet 11:

Soliman PT, Westin SN, Iglesias DA, et al. Everolimus, letrozole, and metformin in women with advanced or recurrent endometroid cancer: a multi-center, single-arm, phase II study. *Clin Cancer Res.* 2020;26:581-587.

Tweet 12:

Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. *Curr Opin Obstet Gynecol.* 2020;32:57-64.

Tweet 14:

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 3.2021—June 3, 2021. Accessed June 15, 2021. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Tweet 15:

Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu (NCT01367002): updated overall survival analysis. *Clin Cancer Res.* 2020;26:3928-3935.

Glossary

AEs, adverse effects/events
AI, aromatase inhibitor
carb, carboplatin
cis, cisplatin
CR, complete response
cyc, cyclophosphamide
dMMR, mismatch repair deficient
DOR, duration of response
dox, doxorubicin
EC, endometrial cancer
EGFR, epidermal growth factor receptor
ERK, extracellular signal-regulated kinases
GI, gastrointestinal
GOG 209, Gynecologic Oncology Group 209 trial
HER2, human epidermal growth factor receptor 2
HT, hormone therapy
MEK, mitogen-activated protein kinase
meta tox, metabolic toxicities
mOS, median overall survival
mPFS, median progression-free survival
MSI-H, microsatellite instability high
mTOR, mechanistic target of rapamycin kinase
NCCN, National Comprehensive Cancer Network
ORR, objective or overall response rate
OS, overall survival
pac, paclitaxel
PFS, progression-free survival
Ph2/Ph3, phase 2 and phase 3
PI3K, phosphoinositide-3-kinase
PN, peripheral neuropathy
PR, partial response
Pt, patient
PTEN, phosphatase and tensin homolog
SD, stable disease
SERD, selective estrogen down-regulator
SERM, selective receptor modulator
TAP, paclitaxel/doxorubicin/cisplatin
TCGA, The Cancer Atlas Program
tras, trastuzumab
TTP, thrombocytopenia
USC, uterine serous carcinoma
w/, with
w/o, without

Drugs: Generic (Trade) Names

carboplatin (Paraplatin)
cisplatin (Platinol)
doxorubicin (Adriamycin or Rubex)
everolimus (Afinitor, Zortress)
letrozole (Femara)
metformin (Glucophage)
paclitaxel (Taxol)
trastuzumab (Herceptin)